Meproleaf
Category
Meproleaf Brand names, Meproleaf Analogs
Meproleaf Brand Names Mixture
Meproleaf Chemical_Formula
C20H23NS
Meproleaf RX_link
No information avaliable
Meproleaf fda sheet
Meproleaf msds (material safety sheet)
Meproleaf Synthesis Reference
No information avaliable
Meproleaf Molecular Weight
309.469 g/mol
Meproleaf Melting Point
< 25 oC
Meproleaf H2O Solubility
Soluble as HCl salt
Meproleaf State
Liquid
Meproleaf LogP
5.7
Meproleaf Dosage Forms
Tablets (oral, 1 mg)
Meproleaf Indication
Used for the symptomatic treatment of parkinsonism.
Meproleaf Pharmacology
Metixene is a tertiary antimuscarinic with actions similar to those of atropine; it also has antihistaminic and direct antispasmodic properties. It is used for the symptomatic treatment of parkinsonism, including the alleviation of the extrapyramidal syndrome induced by other drugs such as phenothiazines, but, like other antimuscarinics, it is of no value against tardive dyskinesias. Metixene has been discontinued.
Meproleaf Absorption
Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.
Meproleaf side effects and Toxicity
Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.
Meproleaf Patient Information
Meproleaf Organisms Affected
Humans and other mammals
